Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety

Dimethyl Fumarate (Tecfidera)

(2014) Jineane V. Venci et al.   ANNALS OF PHARMACOTHERAPY

Current and Future Therapies Targeting the Immune System in Multiple Sclerosis

(2014) Verena Loleit et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Mode of action and clinical studies with fumarates in multiple sclerosis

(2014) Anke Salmen et al.   EXPERIMENTAL NEUROLOGY

Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers

(2013) Sarah I. Sheikh et al.   CLINICAL THERAPEUTICS

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

(2013) Eva Havrdova et al.   EXPERT OPINION ON PHARMACOTHERAPY

Manufacturer's Response to Case Reports of PML

(2013) Marianne T. Sweetser et al.   NEW ENGLAND JOURNAL OF MEDICINE

PML in a Patient Treated with Fumaric Acid

(2013) Ummehan Ermis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

(2012) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target

(2012) Philipp Albrecht et al.   CNS & Neurological Disorders-Drug Targets

Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters

(2012) De-Hyung Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling

(2012) Haiyan Peng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

(2011) Kamran Ghoreschi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action

(2011) Markus Meissner et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Oral treatment for multiple sclerosis

(2011) Joep Killestein et al.   LANCET NEUROLOGY

Phytochemical Induction of Cell Cycle Arrest by Glutathione Oxidation and Reversal by N-Acetylcysteine in Human Colon Carcinoma Cells

(2009) R. Y. Odom et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Temporal trends in the incidence of multiple sclerosis: A systematic review

(2008) A. Alonso et al.   NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE